AACR 2022: Evaluating Delivery of TFR1-targeting Therapies to the CNS in a Novel Humanized TFR1 Mouse Model

AACR 2022: Evaluating Delivery of TFR1-targeting Therapies to the CNS in a Novel Humanized TFR1 Mouse Model

Conclusions

Human TFR1 expression was analyzed in homozygous B-hTFR1 mice by flow cytometry and RT-PCR. When compared with wild type mice, there were no abnormalities in the populations of immune cells in humanized B-hTFR1 mice. In vivo pharmacokinetic analy­ sis of hTFR1-based bispecific antibody indicated that the antibodies were detected at considerably high levels in the brain. The distribution ratio of the bispecific antibody be­ tween the brain and serum showed a time dependent increase, suggesting efficient deliv­ ery to the brain. These data suggest that the B-hTFR1 mouse model is an ideal tool for future in vivo efficacy evaluation of therapeutic B-hTFR1-based bispecific antibodies in preclinical studies.

Related mouse model: B-hTFR1 mice

Share:

    Please fill out the form below to request a download of this poster

    [posterfiledownload]